Irgendwie zeigt w:o die Quartalszahlung der Zealand-Pharma nicht als Meldung an. Ich stelle daher die Mitteilung der Gesellschaft zum Geschäftsverlauf vom 07.02.2018 mal hier rein: Zealand reports royalty revenue for the fourth quarter of 2017 Zealand reports royalty revenue of DKK 11.3 million/USD 1.8 million for Q4 2017 The revenue is based on total net sales of Lyxumia\u00ae/Adlyxin\u00ae and Soliqua\u00ae 100/33/ Suliqua\u00ae of DKK 112.8 million/USD 18.2 million in Q4 2017 In the fourth quarter Soliqua\u00ae 100/33 sales grew 30% over the previous quarter Copenhagen, February 7, 2018 – Zealand Pharma (“Zealand”) reports Q4 2017 royalty revenue from Sanofi’s sales of Soliqua\u00ae 100/33/ Suliqua\u00ae of DKK 7.0 million/USD 1.1 million – an increase of 30% versus previous quarter and from sales of Lyxumia\u00ae/Adlyxin\u00ae (lixisenatide) of DKK 4.3 million/USD 0.7 million. Total royalty revenue for 2017 amounted to DKK 38.8 million/USD 6.3 million an increase of 59% over previous year. Soliqua\u00ae 100/33 is a fixed-dose combination of lixisenatide and insulin glargine 100 units/ml (Lantus\u00ae) which was launched under the brand name Soliqua\u00ae 100/33 in the United States in January 2017 and was also launched as Suliqua\u00ae in some European countries, in 2017. Soliqua\u00ae 100/33/ Suliqua\u00ae is commercialized by Sanofi. Zealand receives 10% of global net sales and potentially up to USD 100 million in commercial milestones. Zealand’s full-year results for 2017 will be published on March 7, 2018. |
|
aus der Diskussion: | mit Zealand Pharma A/S gegen Diabetes |
Autor (Datum des Eintrages): | DrWatch (15.02.18 11:57:11) |
Beitrag: | 1 von 1 (ID:57032166) |
Alle Angaben ohne Gewähr © wallstreetONLINE |